The Comparison of the Initial TIMI Flow Grade in Acute ST-Elevation Myocardial Infarction Patients Receiving...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Primary percutaneous coronary intervention (PCI) is the gold standard treatment for acute ST-elevation myocardial infarction (STEMI).
• Ticagrelor has shown promise in reducing stent thrombosis risk compared to clopidogrel in STEMI patients.
• Optimizing initial coronary blood flow is crucial for improving outcomes in STEMI patients.

Purpose of the Study:

• To compare the initial Thrombolysis In Myocardial Infarction (TIMI) flow between ticagrelor and clopidogrel in STEMI patients undergoing primary PCI.
• To assess the impact of ticagrelor versus clopidogrel on early coronary reperfusion.
• To identify predictors of initial TIMI flow in STEMI patients.

Main Methods:

• A prospective cohort study involving 160 STEMI patients treated at Farshchian Heart Center.
• Patients received either ticagrelor (180 mg) or clopidogrel (600 mg) alongside aspirin before angiography.
• Initial and final TIMI flow grades were assessed, with logistic regression used to analyze predictors of initial flow.

Main Results:

• The ticagrelor group showed a significantly higher initial TIMI flow grade compared to the clopidogrel group (p=0.005).
• Specifically, 12.9% of ticagrelor patients achieved TIMI flow grade III versus 2.5% of clopidogrel patients.
• Ticagrelor was independently associated with a higher likelihood of achieving better initial TIMI flow (adjusted OR: 2.90).

Conclusions:

• Ticagrelor administration resulted in superior initial TIMI flow compared to clopidogrel in STEMI patients undergoing primary PCI.
• These findings suggest ticagrelor may facilitate more effective early reperfusion in STEMI.
• The improved initial flow with ticagrelor could have implications for reducing infarct size and improving clinical outcomes.